Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels
| Autor: | Richard J. Edmondson, Nicola Flaum, Pierre L. Martin-Hirsch, Elaine F. Harkness, D. Gareth Evans, Richard D Clayton, Nicholas J Wood, Fiona Lalloo, Emma R. Woodward, Emma J Crosbie, Cathrine Holland, Patrick J. Keating, P. Donnai |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
medicine.medical_specialty endocrine system diseases Peritoneal cancer business.industry Future risk Oncological surgery Serous Tubal Intraepithelial Carcinoma Gastroenterology Occult 03 medical and health sciences 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Internal medicine medicine Serous ovarian cancer Occult cancer Stage (cooking) business |
| Zdroj: | International Journal of Cancer. 148:1155-1163 |
| ISSN: | 1097-0215 0020-7136 |
| DOI: | 10.1002/ijc.33378 |
| Popis: | Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is highly effective for the prevention of high-grade serous ovarian cancer (HGSOC) in BRCA1/2 pathogenic variant carriers (PVCs), but does not completely eliminate future risk of primary peritoneal cancer (PPC). The requirement to completely remove fallopian tubes at RRBSO and carefully exclude occult cancer/serous tubal intraepithelial carcinoma (STIC) lesions may not have been appreciated historically. We calculated rates of HGSOC and PPC in confirmed BRCA1/2 PVCs registered on the regional database in those who did (cases) and did not (controls) undergo RRBSO after genetic testing. Expected annual rates of ovarian/peritoneal cancer were 1% for BRCA1 ≥ 35 years and 0.5% for BRCA2 ≥ 45 years. Follow-up before 35/45 years was "risk free" and lead time excluded RRBSO |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text